Literature DB >> 19091987

Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors.

Miriam Melis1, Giuliano Pillolla, Antonio Luchicchi, Anna Lisa Muntoni, Sevil Yasar, Steven R Goldberg, Marco Pistis.   

Abstract

Nicotine stimulates the activity of mesolimbic dopamine neurons, which is believed to mediate the rewarding and addictive properties of tobacco use. Accumulating evidence suggests that the endocannabinoid system might play a major role in neuronal mechanisms underlying the rewarding properties of drugs of abuse, including nicotine. Here, we investigated the modulation of nicotine effects by the endocannabinoid system on dopamine neurons in the ventral tegmental area with electrophysiological techniques in vivo and in vitro. We discovered that pharmacological inhibition of fatty acid amide hydrolase (FAAH), the enzyme that catabolizes fatty acid ethanolamides, among which the endocannabinoid anandamide (AEA) is the best known, suppressed nicotine-induced excitation of dopamine cells. Importantly, this effect was mimicked by the administration of the FAAH substrates oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), but not methanandamide, the hydrolysis resistant analog of AEA. OEA and PEA are naturally occurring lipid signaling molecules structurally related to AEA, but devoid of affinity for cannabinoid receptors. They blocked the effects of nicotine by activation of the peroxisome proliferator-activated receptor-alpha (PPAR-alpha), a nuclear receptor transcription factor involved in several aspects of lipid metabolism and energy balance. Activation of PPAR-alpha triggered a nongenomic stimulation of tyrosine kinases, which might lead to phosphorylation and negative regulation of neuronal nicotinic acetylcholine receptors. These data indicate for the first time that the anorexic lipids OEA and PEA possess neuromodulatory properties as endogenous ligands of PPAR-alpha in the brain and provide a potential new target for the treatment of nicotine addiction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19091987      PMCID: PMC3169176          DOI: 10.1523/JNEUROSCI.3221-08.2008

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  56 in total

1.  Excitatory and inhibitory responses of dopamine neurons in the ventral tegmental area to nicotine.

Authors:  Sophie Erhardt; Lilly Schwieler; Göran Engberg
Journal:  Synapse       Date:  2002-03-15       Impact factor: 2.562

2.  Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum.

Authors:  F M Zhou; Y Liang; J A Dani
Journal:  Nat Neurosci       Date:  2001-12       Impact factor: 24.884

3.  The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport.

Authors:  Marcello Solinas; Gianluigi Tanda; Zuzana Justinova; Carrie E Wertheim; Sevil Yasar; Daniele Piomelli; Subramanian K Vadivel; Alexandros Makriyannis; Steven R Goldberg
Journal:  J Pharmacol Exp Ther       Date:  2007-01-08       Impact factor: 4.030

Review 4.  The mechanisms of action of PPARs.

Authors:  Joel Berger; David E Moller
Journal:  Annu Rev Med       Date:  2002       Impact factor: 13.739

5.  An anorexic lipid mediator regulated by feeding.

Authors:  F Rodríguez de Fonseca; M Navarro; R Gómez; L Escuredo; F Nava; J Fu; E Murillo-Rodríguez; A Giuffrida; J LoVerme; S Gaetani; S Kathuria; C Gall; D Piomelli
Journal:  Nature       Date:  2001-11-08       Impact factor: 49.962

6.  Acute intracerebroventricular administration of palmitoylethanolamide, an endogenous peroxisome proliferator-activated receptor-alpha agonist, modulates carrageenan-induced paw edema in mice.

Authors:  Giuseppe D'Agostino; Giovanna La Rana; Roberto Russo; Oscar Sasso; Anna Iacono; Emanuela Esposito; Giuseppina Mattace Raso; Salvatore Cuzzocrea; Jesse Lo Verme; Daniele Piomelli; Rosaria Meli; Antonio Calignano
Journal:  J Pharmacol Exp Ther       Date:  2007-06-12       Impact factor: 4.030

7.  Bovine serum albumin enhances nicotinic acetylcholine receptor function in mouse thalamic synaptosomes.

Authors:  Christopher M Butt; Scott R Hutton; Michael J Marks; Allan C Collins
Journal:  J Neurochem       Date:  2002-10       Impact factor: 5.372

8.  SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats.

Authors:  C Cohen; G Perrault; C Voltz; R Steinberg; P Soubrié
Journal:  Behav Pharmacol       Date:  2002-09       Impact factor: 2.293

Review 9.  Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation.

Authors:  K Cahill; M Ussher
Journal:  Cochrane Database Syst Rev       Date:  2007-07-18

10.  The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.

Authors:  Roberto Russo; Jesse Loverme; Giovanna La Rana; Timothy R Compton; Jeff Parrott; Andrea Duranti; Andrea Tontini; Marco Mor; Giorgio Tarzia; Antonio Calignano; Daniele Piomelli
Journal:  J Pharmacol Exp Ther       Date:  2007-04-05       Impact factor: 4.030

View more
  73 in total

Review 1.  Animal models of cannabinoid reward.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 2.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  The peroxisome proliferator-activated receptor alpha agonist fenofibrate attenuates alcohol self-administration in rats.

Authors:  Colin N Haile; Therese A Kosten
Journal:  Neuropharmacology       Date:  2017-01-11       Impact factor: 5.250

4.  Dual role of PPAR-γ in induction and expression of behavioral sensitization to cannabinoid receptor agonist WIN55,212-2.

Authors:  Leili Enayatfard; Farzaneh Rostami; Sanaz Nasoohi; Shahrbanoo Oryan; Abolhassan Ahmadiani; Leila Dargahi
Journal:  Neuromolecular Med       Date:  2013-06-21       Impact factor: 3.843

5.  Effects of fatty acid amide hydrolase inhibition on neuronal responses to nicotine, cocaine and morphine in the nucleus accumbens shell and ventral tegmental area: involvement of PPAR-alpha nuclear receptors.

Authors:  Antonio Luchicchi; Salvatore Lecca; Stefano Carta; Giuliano Pillolla; Anna L Muntoni; Sevil Yasar; Steven R Goldberg; Marco Pistis
Journal:  Addict Biol       Date:  2010-05-11       Impact factor: 4.280

6.  Inhibition of monoacylglycerol lipase reduces nicotine reward in the conditioned place preference test in male mice.

Authors:  Pretal P Muldoon; Lois S Akinola; Joel E Schlosburg; Aron H Lichtman; Laura J Sim-Selley; Anu Mahadevan; Benjamin F Cravatt; M Imad Damaj
Journal:  Neuropharmacology       Date:  2020-05-30       Impact factor: 5.250

7.  Effects of drugs of abuse on putative rostromedial tegmental neurons, inhibitory afferents to midbrain dopamine cells.

Authors:  Salvatore Lecca; Miriam Melis; Antonio Luchicchi; Maria Grazia Ennas; Maria Paola Castelli; Anna Lisa Muntoni; Marco Pistis
Journal:  Neuropsychopharmacology       Date:  2010-11-03       Impact factor: 7.853

Review 8.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

9.  AM404 attenuates reinstatement of nicotine seeking induced by nicotine-associated cues and nicotine priming but does not affect nicotine- and food-taking.

Authors:  Islam Gamaleddin; Mihail Guranda; Maria Scherma; Walter Fratta; Alexandros Makriyannis; Subramanian K Vadivel; Steven R Goldberg; Bernard Le Foll
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

Review 10.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.